Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study

被引：0

作者：

Lucheng ZHU

Changlin Zou

Zhanchun Zhang

Jianfang Wang

Li Yang

Chuangzhou Rao

Zhiping Yang

Jiafeng Liang

Bing Xia

M. A. Shenglin

机构：

[1] Affiliated Hangzhou Cancer Hospital,Department of Thoracic Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province

[2] Zhejiang University School of Medicine,Department of Radiotherapy

[3] The First Affiliated Hospital of Wenzhou Medical University,Department of Radiotherapy

[4] Ningbo Medical Center Lihuili Hospital,Department of Radiotherapy, Shaoxing People’s Hospital (Shaoxing Hospital

[5] Zhejiang University School of Medicine),Department of Pulmonary & Critical Care Medicine, Shulan (Hangzhou) Hospital

[6] Affiliated to Zhejiang Shuren University Shulan International Medical college,Department of Radiotherapy & Chemotherapy,Hwa Mei Hospital

[7] University of Chinese Academy of Sciences,Department of Oncology, Affiliated Hospital of Jiaxing University

[8] The First Hospital of Jiaxing,Department of Oncology

[9] Jiande Second People’s Hospital,Department of Cancer Medical Center

[10] Affiliated Xiaoshan Hospital,undefined

[11] Hangzhou Normal University,undefined

来源：

BMC Cancer | / 21卷

关键词：

Almonertinib; EGFR-TKI; Radiotherapy; Locally advanced NSCLC; Radiation pneumonitis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study [J].

Zhu, Lucheng ;

Zou, Changlin ;

Zhang, Zhanchun ;

Wang, Jianfang ;

Yang, Li ;

Rao, Chuangzhou ;

Yang, Zhiping ;

Liang, Jiafeng ;

Xia, Bing ;

Shenglin, M. A. .

BMC CANCER, 2021, 21 (01)

[2] Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer [J].

Rizvi, Naiyer A. ;

Peters, Solange .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1986-1988

[3] Almonertinib With Radiotherapy vs Concurrent Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC (ADVANCE Trial) [J].

Bi, N. ;

Jiang, W. ;

Chen, M. ;

Fu, X. L. ;

Wang, L. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) :S1104-S1105

[4] EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI? [J].

Liu, Bailong ;

Liu, Hui ;

Ma, Yunfei ;

Ding, Qiuhui ;

Zhang, Min ;

Liu, Xinliang ;

Liu, Min .

CANCER MEDICINE, 2021, 10 (18) :6167-6188

[5] Concurrent cisplatin, etoposide, and radiotherapy for unresectable Stage III nonsmall cell lung cancer: A Phase II study [J].

Reboul, F ;

Brewer, Y ;

Vincent, P ;

Chauvet, B ;

Faure, CF ;

Taulelle, M .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (02) :343-350

[6] Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer [J].

Xu, Kunpeng ;

Liang, Jun ;

Zhang, Tao ;

Zhou, Zongmei ;

Chen, Dongfu ;

Feng, Qinfu ;

Xiao, Zefen ;

Hui, Zhouguang ;

Lu, Jima ;

Wang, Xin ;

Deng, Lei ;

Liu, Wenyang ;

Wang, Jianyang ;

Zhai, Yirui ;

Wang, Jie ;

Bi, Nan ;

Wang, Luhua .

THORACIC CANCER, 2021, 12 (06) :814-823

[7] Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer [J].

Yoshinobu Iwasaki ;

Shuji Ohsugi ;

Atsushi Natsuhara ;

Takuji Tsubokura ;

Hidehiko Harada ;

Mikio Ueda ;

Taichiro Arimoto ;

Hiroshi Hara ;

Tadaaki Yamada ;

Toshiyuki Takesako ;

Kenji Kohno ;

Shigekuni Hosogi ;

Masaki Nakanishi ;

Yoshinori Marunaka ;

Tsunehiko Nishimura .

Cancer Chemotherapy and Pharmacology, 2006, 58 :735-741

[8] Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial [J].

Martinez, Enrique ;

Martinez, Maite ;

Rico, Mikel ;

Hernandez, Berta ;

Casas, Francesc ;

Vinolas, Nuria ;

Perez-Casas, Ana ;

Domine, Manuel ;

Minguez, Julian .

ONCOTARGETS AND THERAPY, 2016, 9 :1057-1066

[9] RANDOMIZED PHASE II TRIAL OF URACIL/TEGAFUR (UFT) AND CISPLATIN VERSUS VINORELBINE AND CISPLATIN WITH CONCURRENT THORACIC RADIOTHERAPY FOR LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL-CELL LUNG CANCER: NJLCG 0601 [J].

Watanabe, Hiroshi ;

Sugawara, Shunichi ;

Maemondo, Makoto ;

Tachihara, Motoko ;

Sakakibara, Tomohiro ;

Ishida, Takashi ;

Inoue, Akira ;

Usui, Kazuhiro ;

Ishimoto, Osamu ;

Matsubara, Nobumichi ;

Saijo, Yasuo ;

Nukiwa, Toshihiro .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) :S490-S491

[10] PHASE I STUDY OF CONCURRENT HIGH-DOSE THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY WITH CHEMOTHERAPY USING CISPLATIN AND VINORELBINE FOR UNRESECTABLE STAGE III NON-SMALL-CELL LUNG CANCER [J].

Sekine, Ikuo ;

Sumi, Minako ;

Ito, Yoshinori ;

Horinouchi, Hidehito ;

Nokihara, Hiroshi ;

Yamamoto, Noboru ;

Kunitoh, Hideo ;

Ohe, Yuichiro ;

Kubota, Kaoru ;

Tamura, Tomohide .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (02) :953-959

← 1 2 3 4 5 →